IceCure Medical Ltd. announced interim results from the Company's ICE3 clinical trial for cryoablation of small low-risk breast cancer tumors. At a mean of 34.83 months following treatment with ProSense®, only 2.06% (4 out of 194 eligible trial patients) experienced cancer recurrence. Interim results were presented at the 22nd Annual Meeting of the American Society of Breast Surgeons (ASBrS) by Dr. Richard Fine, MD, FACS, an ICE3 investigator who serves as Program Director of the Breast Surgical Oncology Fellowship and as Director of Research and Education at the West Comprehensive Breast Center in Germantown, TN, who previously served as Chairman of the ASBrS. The ICE3 trial commenced in 2014 and is, to the best of the Company's knowledge, the largest controlled multisite clinical trial conducted in the U.S. for liquid nitrogen-based cryoablation of early-stage malignant breast tumors. The study was conducted in 19 hospitals and medical centers across the U.S., including Columbia University Medical Center and Mount Sinai Beth Israel. The ICE3 trial enrolled and treated 194 patients 55 years of age or older (average age of 75) with low-risk, early-stage breast cancer tumors measuring up to 1.5 cm. Patients were treated with IceCure's ProSense® Cryoablation System, a minimally-invasive approach to directly target and freeze tumors. Duration of treatment ranged from 20 to 40 minutes depending on the location and size of the tumor. Treatment does not require surgical incision or involve scarring. At a mean of 34.83 months following treatment with ProSense®, only 2.06% (4 patients) experienced cancer recurrence. The 36-month local Failure Free Probability is 99.22%. The statistical analysis presented by Dr. Fine indicates that among patients treated using the company's ProSense® Cryoablation System, the chance of non-recurrence in a population of patients with low-risk breast cancer, in early stages, and up to 1.5 cm tumor size, for a period of up to three years, is between 94.58%% and 99.89%%, with a statistical significance (confidence level) of 95%. He also reported that freezing low risk breast tumors in the early stages delivers greater patient satisfaction at a lower cost than traditional interventions. In keeping with that trend, cryoablation is a promising, high value treatment for certain forms of less aggressive cancers. No significant device-related adverse events were reported. 95% percent of patients and 98% of treating physicians reported satisfaction with the cosmetic results. IceCure expects that by June 2021 there will be 49 patients that have completed a five-year follow-up, 41 patients that have completed a four-year follow-up, 39 patients that have completed a three-year follow-up, and 51 patients that have completed a two-year follow-up.